

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : Not classified		A2	(11) International Publication Number: WO 95/02420 (43) International Publication Date: 26 January 1995 (26.01.95)
(21) International Application Number: PCT/GB94/01532 (22) International Filing Date: 15 July 1994 (15.07.94)		(81) Designated States: AU, CA, HU, JP, KR, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 9314703.1 15 July 1993 (15.07.93) GB 9314702.3 15 July 1993 (15.07.93) GB		Published Without international search report and to be republished upon receipt of that report.	
(71)(72) Applicants and Inventors: SPRINGER, Caroline, Joy [GB/GB]; The Institute of Cancer Research, The Royal Marsden Hospital, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 2NG (GB). MARAIS, Richard [GB/GB]; Chester Beatty Laboratories, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB (GB).			
(74) Agents: BRASNETT, Adrian, Hugh et al.; J.A. Kemp & Co, 14 South Square, Gray's Inn, London WC1R 5LX (GB).			

(54) Title: PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS

(57) Abstract

A compound which comprises a prodrug of a protein tyrosine kinase inhibitor (PTKI) linked to a protecting group, said group being capable of being cleaved from said compound to release the protein tyrosine kinase inhibitor. Protein tyrosine kinase inhibitors include tyrphostins, preferably those of formula (I), where X represents carbon, a nitrogen or a group N→O, n is an integer from 1 to 3; each group R¹, which may be the same or different is hydrogen, hydroxy, mercapto, carboxy, formyl, C₁₋₄alkyl, C₂₋₄ alkenyl, C₁₋₄alkoxy, C₁₋₄alkylthio, carboxy, C₁₋₄alkyl, carboxyC₂₋₄ alkenyl, C₁₋₄alkylsulphoxy, halo (i.e. fluoro, chloro, bromo or iodo), nitro, amino, C₁₋₄alkylamino, or C₁₋₄dialkylamino, or when n is 2 or 3 two R¹ groups may together form a methylenedioxy or ethylenedioxy group; R² is hydrogen, hydroxy, C₁₋₄alkyl or together with position 2 of the ring to which the group(s) R¹ is (are) attached forms a 5 or 6 membered aliphatic or heterocyclic ring, said 5 or 6 membered ring optionally containing a ketone group; and R³ is cyano, carboxy, carbamoyl, thiocarbamoyl, a group C(O)HNCH₂CN, a group C(NH₂)=C(CN₂), an alpha keto group C(O)R⁴ where R⁴ is 3,4-dihydroxyphenyl or 2-thiophene or an alpha amido group C(O)NHR⁵ where R⁵ is benzyl, phenyl, or 2,4-dimethoxyphenyl; provided that at least one of the groups R¹ and R² are mercapto, hydroxy or amino.



(I)

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS

The present invention relates to prodrugs and their use in the treatment of tumours.

5 The use of prodrugs represents a clinically very valuable concept in cancer therapy since, particularly where the prodrug is to be converted to an anti-tumour agent under the influence of an enzyme that is linkable to a monoclonal antibody that will bind to a tumour associated antigen, the combination of such a prodrug with such an enzyme
10 monoclonal/antibody conjugate represents a very powerful clinical agent. This approach to cancer therapy, often referred to as "antibody directed enzyme/prodrug therapy" (ADEPT) is disclosed in WO88/07378.

More recently, a similar approach ("VDEPT") has been proposed where in place of an antibody/enzyme conjugate, tumour cells
15 are targeted with a viral vector carrying a gene encoding an enzyme capable of activating a prodrug. The gene may be transcriptionally regulated by tumour specific promoter or enhancer sequences. The viral vector enters tumour cells and expresses the enzyme, in order that a prodrug is converted to
20 an active drug only in the vicinity of the tumour cells (Huber et al, Proc. Natl. Acad. Sci. USA (1991) 88, 8039). Alternatively, non-viral methods for the delivery of genes have been used. Such methods include calcium phosphate co-precipitation, microinjection, liposomes, direct DNA uptake,
25 and receptor-mediated DNA transfer. These are reviewed in Morgan & French Anderson, Annu. Rev. Biochem., 1993, 62;191. The term "GDEPT" (gene-directed enzyme prodrug therapy) is used to include both viral and non-viral delivery systems.

30 Although the GDEPT and ADEPT systems enhance the concentrations of anti-tumour agents which may be delivered to the site of a tumour, there is still a need to enhance the

- 2 -

specificity of drug delivery. In both systems, active drug can be released into the environment of normal cells and cause damage. In the case of ADEPT, this can be caused by activation of prodrug by conjugates which have failed to localise at the tumour site. In GDEPT, transformation of normal tissue may lead to residual levels of expression of the enzyme away from the tumour or active drug may be released from tumour cells. Although ways to increase the specificity of the ADEPT system is disclosed in WO89/10140, there remains a continuing need to improve the level of ADEPT and GDEPT specificity.

The present invention addresses such problems by the use of a novel class of prodrugs, which are prodrugs of protein tyrosine kinase (PTK) inhibitors. Some PTKs are known to be over-expressed by some types of tumours such as in breast and ovarian carcinomas, where the cErbB2 gene is over-expressed. Certain compounds have been found to be selective for PTKs and thus are relatively non toxic to cells which do not over-express PTKs.

The use of such compounds in ADEPT or GDEPT thus provides an increased level of specificity for the treatment of tumour cells. Prodrugs based upon PTK-inhibitors will be converted into PTK inhibitors primarily at the site of a tumour, but at the same time release of PTK-inhibitors at other sites or from the tumour will not cause cytotoxicity comparable to the release of non-specific cytotoxic drugs.

In one aspect, the present invention provides a compound which comprises a prodrug of a protein tyrosine kinase inhibitor (PTKi) linked to at least one protecting group said group being capable of being cleaved from said compound to release the protein tyrosine kinase inhibitor or a physiologically acceptable derivative of said prodrug.


- 3 -

The prodrug is of the general formula:

PTKi-PRT

where PTKi compound is a compound with PTK inhibitory activity and PRT is at least one protecting group capable of being cleaved from the PTK inhibitor by the action of an enzyme.

Suitable PTKs include tyrphostins. Tyrphostins are low molecular weight (e.g. less than 2,000) styryl containing inhibitors of protein tyrosine kinase which are capable of binding to the subsite of protein tyrosine kinase domains. Suitable tyrphostins include those described by Gazit et al (Gazit et al, J. Med. Chem. (1989) 32, 2344) and Gazit et al (J. Med. Chem. (1991) 43; 1896-1907) and especially tyrphostins of the general formula (I)



where X represents carbon, a nitrogen or a group N→O,
 n is an integer from 1 to 3;
 each group R¹, which may be the same or different is hydrogen, hydroxy, mercapto, carboxy, formyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₁₋₄alkoxy, C₁₋₄alkylthio, carboxyC₁₋₄alkyl, carboxyC₂₋₄alkenyl, C₁₋₄alkylsulphoxy, halo (ie. fluoro, chloro, bromo or iodo), nitro, amino, C₁₋₄alkylamino, or C₁₋₄dialkylamino, or when n is 2 or 3 two R¹ groups may together form a methylenedioxy or ethylenedioxy group;
 R² is hydrogen, hydroxy, C₁₋₄alkyl or together with position 2 of the ring to which the group(s) R¹ is(are) attached forms a 5 or 6 membered aliphatic or heterocyclic ring, said 5 or 6

- 4 -

membered ring optionally containing a ketone group; and
R³ is cyano, carboxy, carbamoyl, thiocarbamoyl, a group
C(O)HNCH₂CN, a group C(NH₂)=C(CN)₂, an alpha keto group C(O)R⁴
where R⁴ is 3,4-dihydroxyphenyl or 2-thiophenyl or an alpha
5 amido group C(O)NHR⁵ where R⁵ is benzyl, phenyl or 2,4-
dimethoxyphenyl;
provided that at least one of the groups R¹ and R² is
mercapto, hydroxy or amino.

10 In a preferred embodiment, X is C; n is an integer from 1 to
3; each group R¹, which may be the same or different is
hydrogen, hydroxy, carboxy, formyl, C₁₋₄alkyl, C₂₋₄ alkenyl, C₁₋₄
alkoxy, carboxyC₁₋₄alkyl, carboxyC₂₋₄ alkenyl, halo (ie.
fluoro, chloro, bromo or iodo), nitro, amino, C₁₋₄alkylamino,
15 or C₁₋₄dialkylamino, or when n is 2 or 3 two R¹ groups may
together form a methylenedioxy or ethylenedioxy group; R² is
hydrogen, hydroxy or C₁₋₄alkyl; and R³ is cyano, carboxy,
carbamoyl, thiocarbamoyl, a group C(O)HNCH₂CN or a group
C(NH₂)=C(CN)₂.

20 Most preferably, X represents carbon, n is an integer from 1
to 3; each group R¹, which may be the same or different is
hydrogen, hydroxy or amino; R² is hydrogen or hydroxy; and
R³ is cyano, a group C(O)HNCH₂CN, a group C(NH₂)=C(CN)₂, an
alpha keto group C(O)R⁴ where R⁴ is 3,4-dihydroxyphenyl, or
an alpha amido group C(O)NHR⁵ where R⁵ is benzyl; provided
25 that at least one of the groups R¹, R², and R³ are hydroxy or
amino.

Preferably, R¹ is hydroxy or amino.

30 When R² forms a 5 or 6 membered ring with R¹ preferred rings
include heterocyclic rings wherein the ring contain one
nitrogen atom and 4 or 5 carbon atoms. The total number of
atoms includes the 2 carbon atoms of the ring to which the
group(s) R¹ is(are) attached.

- 5 -

Suitable tyrphostins such as the above may be obtained by the methods disclosed in, or analogous to those of, Gazit et al 1989 and 1991, *ibid*, which are incorporated herein by reference.

5 Other PTK inhibitors include flavonoids, erbstatin, benzoquinoid ansamycin antibiotics and various peptide and nucleotide analogues. The exact nature of the PTKi will depend upon the particular target tumour for which the PTKi is to be used, taking into account the nature of the
10 particular PTK involved. This can be determined by those of skill in the art, for example by culture of a biopsy sample of the tumour in the presence of a range of candidate PTKs. Suitable PTKs may be found in Workman et al, *Seminars in Cancer Biology*, Vol 3 (1992), 369-381.

15 PTK inhibitors may be linked to any suitable protecting group which is removable by an enzyme. Examples of such groups include those found in WO88/07378 or in WO93/08288. For example, WO93/08288 describes "self immolative" prodrugs which can be activated by the action of a nitroreductase
20 enzyme. These prodrugs are derivatives of p-nitrobenzyloxycarbonyl compounds.

The exact structure of the protecting group will depend upon the nature of the ADEPT or GDEPT system with which a tyrphostin prodrug is to be used. It may be any suitable
25 group which can be removed by an enzyme or modified by the enzyme in such a manner that the group is unstable and undergoes "self immolation" to provide the active PTK.

The number of protecting groups attached to each PTKi will depend in part upon the exact structure of the inhibitor
30 compound. It will also depend upon the relative activity of the unprotected PTKi to the PTKi when different numbers of protecting groups are added, since if additional protecting

- 6 -

groups will achieve a reduction in potency of the prodrug
this will increase the ratio of activity of PTKi to PTKi-PRT.

Desirably, one or two protecting groups will be attached to
each PTKi molecule to provide a compound of the invention,
5 although more, e.g. 3, 4 or 5 groups may be added where the
PTKi is of a structure which will allow this number to be
linked.

Accordingly, prodrugs according to the invention include
compounds with a protecting group of the formula (II):

10
$$\text{PTK}-(\text{X}-\text{CO}-\text{O}-\text{CH}_2-\text{Ph}-\text{NO}_2)_m \quad (\text{II})$$

where X is NH, O or S, m is an integer from 1 to 5 (e.g. 1,
2 or 3), Ph is an optionally substituted phenylene ring and
PTK is a group such that $\text{PTK}-(\text{XH})_m$ is a PTKi containing m -XH
15 groups. The nitro group may be in the 2-position although is
desirably in the 4-position of the ring relative to the Ph
ring.

Within each compound of formula (II) where m from 2 to 5,
each group X and Ph may be the same or different.
Preferably, they are the same.


20 PTK inhibitors of formula (II) include tyrphostins including
those of formula (I) above in which at least one of the
groups R^1 and R^2 is an hydroxy, mercapto or amino group.

Suitable substituents of the phenylene ring include 1 to 4
groups which may be the same or different which are selected
25 from fluorine, chlorine, bromine, iodine, hydroxy, mercapto,
amino, nitro, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4}
haloalkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, and C_{2-4} haloalkenyl.
Preferably, the substituents are from 1 to 4 fluorines in the
2, 3, 5 and 6 positions of the ring.

30 Preferred prodrugs according to the invention are those of


- 7 -

formula (III):



where m and Ph is as defined above and PTK is a group such that $\text{PTK}-(\text{OH})_m$ is a PTKi compound containing m hydroxyl groups. Such prodrugs include those tyrphostins of formula (I) above in which at least one of the groups R^1 , R^2 or R^3 is a hydroxyl group. The nitro group may be in the 2-position although is desirably in the 4-position of the ring relative to the Ph ring.

Compounds of formulae (II) and (III) may be used as prodrugs in an ADEPT or GDEPT system in conjunction with a nitroreductase enzyme, including the *E.coli* nitroreductase described in WO93/08288. While the present invention is not dependent, for its definition, upon the exact mode of action of the nitroreductase on the compound of formula II or III, it is believed that the nitro group of the optionally substituted p-nitrophenyl-benzyloxy-carbonyl residue is converted to the corresponding amino or hydroxylamino group and that the resulting optionally substituted p-aminobenzyloxy-carbonyl or optionally substituted p-hydroxylaminobenzyloxycarbonyl compound automatically degrades under the reaction conditions used for the enzymatic reduction to release the cytotoxic compound and form optionally substituted p-aminobenzyl alcohol or optionally substituted p-hydroxylaminobenzyl alcohol and carbon dioxide as by products in accordance with the following reaction scheme:




The optionally substituted p-nitrobenzyloxycarbonyl compounds of the invention are conveniently prepared by methods of


- 8 -

chemical synthesis known per se. For example, the amine or hydroxy PTKi compounds can be reacted with optionally substituted 4-nitrobenzyl chloroformate under anhydrous conditions in the presence of a hydrogen chloride acceptor, particularly an alkylamine such as triethylamine. This reaction can be carried out in a dry aprotic organic solvent such as THF or chloroform and the resulting compound of the invention of formula II or formula III purified from the organic solvent by conventional methods such as chromatography or recrystallization. For use in ADEPT the prodrug should be unable to or have limited ability to enter cells, whereas for GDEPT the prodrug should enter cells. Accordingly, modifications may be made in the prodrug, eg in the benzene ring, to make the prodrug more, or less, lipophilic.


Similar prodrugs which can be activated by a carboxypeptidase enzyme such as carboxypeptidase G2 (CPG2) can be made using benzyl haloformate (where halo is fluoro, chloro or bromo, preferably chloro) derivatives of the formula (IV):




where Q is hydrogen or fluoro, chloro or bromo, Ph is as defined above, Z is -O.CO- or -NH.CO- and glu is the residue of glutamic acid, ie a group:



or a di-C₁₋₆ alkyl ester (e.g. an ethyl or t-butyl ester) thereof, in order to provide prodrugs of the formula (V):



and of the formula (VI)



where PTK is the residue of a PTKi compound such that PTK-(XH)_m and PTK-(OH)_m are as defined above, and where m, Ph, Z and glu are also as defined above. As mentioned above in connection with prodrugs of formula (II) and formula (III), for ADEPT the prodrug should have limited ability to enter cells whereas for GDEPT the prodrug may be modified if need

- 9 -

be to make it more lipophilic in order that it does enter cells. The gamma carboxylic group of the glutamic acid may be altered to make compounds that are more lipophilic, e.g. with an aromatic or heterocyclic amide.

- 5 Within each compound of formula (V) where m from 2 to 5, each group X and Ph may be the same or different. Preferably, they are the same.

10 In compounds of formulae (IV), (V) and (VI), the group -Z- is in the 4-position of the ring relative to the PTK containing substituent.

Compounds of the formula (V) and (VI) in which the PTK is a tyrphostin, especially a tyrphostin of formula (I) are preferred.

15 The benzyl chloroformate derivatives of the formula (IV) in which Z is -NH.CO- may be made from 4-(chloromethyl)phenyl isocyanate by reaction of glutamic acid or a protected derivative thereof, eg in which both carboxy groups of the glutamic acid residue are protected with C₁₋₆ alkyl such as ethyl or t-butyl groups. Suitably, the reaction is carried
20 out in a solvent such as CH₂Cl₂ at about room temperature. The resulting intermediate, [4-chloromethyl]phenyl-ureidoglutamate-di-tert-butylester, is treated in aqueous ethanol under reflux to provide the corresponding 4-hydroxymethyl compound and this is reacted with triphosgene
25 ((CCl₃O)₂CO) in an inert solvent, eg. THF, at room temperature to provide an optionally protected compound of formula (IV). The compound when protected may be deprotected by treatment with trifluoroacetic acid or formic acid.

30 The benzyl chloroformate derivatives of the formula (IV) in which Z is -O.CO- may be made starting from 4-hydroxybenzaldehyde. Briefly, the aldehyde is treated with


- 10 -

1,2-ethane dithiol in borane trifluoroetherate plus CH_2Cl_2 at 25°C for about 12 hours to form the 1,3 dithiolane intermediate which is treated with triphosgene as above to form the 4[1,3 dithiolane] phenylchloroformate. This is coupled with ditertbutyl-glutamate hydrochloride in dry THF in the presence of triethylamine at room temperature for about 5 hours, to provide 4[1,3 dithiolane] phenylcarbamate-glutamate-di-tbutyl. The dithiolane is deprotected with mercuric perchloroate in methanol or THF and chloroform at about 25°C for about 5 minutes. The aldehyde is converted to the corresponding benzylic alcohol by mild reduction with sodium borohydride or other mild reducing agents at room temperature in ether and then converted to the corresponding chloroformate with triphosgene as described above.

Compounds of the formula (V) and (VI) may be made from PTK inhibitors which contain an amino or hydroxy group by analogous procedures to the methods described above for the production of compounds of formulae (II) and (III).

PTK prodrugs of the formulae (V) or (VI) will be activated by carboxypeptidases such as CPG2 by the action of the enzyme to remove the glutamic acid residue followed by "self immolation" of the remaining prodrug in a manner analogous to that described above in relation to the nitroreductases.

Prodrugs of the formula (V) where Z is $-\text{NH}\cdot\text{CO}-$ may also be made using novel linkers of the formula (VII):



where Ph and glu are as defined above. The optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the hydroxymethyl group.

Thus in a further aspect, the invention provides novel linkers of the formula (VII). The linkers may also be linked

- 11 -

to other pharmaceutical compounds containing a free hydroxy, amino or mercapto group to provide novel prodrugs and such prodrugs form an additional aspect of the invention. The novel prodrugs may be prepared as pharmaceutical compositions and may be used in the treatment of patients using ADEPT or GDEPT as described herein.

The novel linkers of formula (VII) may be made from optionally substituted 4-nitrobenzyl alcohol, where the optional substituents are as defined for the group -Ph- above. The hydroxyl group of the 4-nitrobenzyl alcohol is protected, for example by reaction with tert-butyl-diphenyl-chloro-silane at room temperature in an organic solvent, to provide an optionally substituted (4-nitro-benzyl) tert-butyl-di-phenyl-silyl ether. The 4-nitro group is then reduced to an amine group by catalytic hydrogenation or catalytic hydrogen transfer, for example with ammonium formate in the presence of a catalyst such as Pd/C in a protic solvent such as an alcohol, e.g. methanol or ethanol.

The amine group may then be converted into an isocyanate group for example by reaction with phosgene, diphosgene or triphosgene in the presence of a tertiary organic amine such as triethylamine and an aprotic organic solvent with a boiling point higher than 50°C such as toluene. The isocyanate compound is then reacted with di-C₁₋₆alkyl-glutamic acid or derivative thereof, eg di-C₁₋₆alkyl-glutamate hydrochloride. This may be done at room temperature in the presence of triethylamine in an aprotic organic solvent such as toluene, THF or dichloromethane.

Alternatively, the amine compound may be reacted directly in a one-pot synthesis with the di-C₁₋₆alkyl-glutamic acid or derivative thereof in the presence of triphosgene and triethylamine in an aprotic solvent such as THF or dichloromethane.


- 12 -

In either case, the resulting compound is treated to remove the hydroxy-protecting group, for example by the use of tetra-butylammonium fluoride in THF at room temperature.

5 The resulting compound of formula (VII) where glu is in the form of a di-C₁₋₆alkyl ester may be deprotected to remove the ester groups for example by the use of an acid such as formic or trifluoro acetic acid. Alternatively, it may be linked to a PTKi containing a group -OH, -NH₂ or -SH by reaction with
10 the PTKi or activated derivative thereof in aprotic solvents such as dichloromethane and/or THF in the presence of a tertiary organic base such as triethylamine at room temperature, to provide a compound of the formula (V). The di-C₁₋₆alkyl ester groups of the compound, if present, may be removed as described above.

15 In order to link a PTKi with a group -XH to the novel linker of formula (VII) the group -XH may be converted to a reactive chloroformyl, chlorothioformyl or isocyanate derivative by the use of phosgene, diphosgene or triphosgene in the presence of a phase transfer catalyst such as tetra-butyl
20 ammonium hydrogen sulphate. The reaction may be carried out in the presence of a base such as NaOH in an organic solvent such as toluene, THF or dichloromethane.

In a further aspect of the invention, prodrugs of the formula (V) in which Z is -O.CO- may be made using novel linkers of
25 the formula (VIII):



where Ph and glu are as defined above. The optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the hydroxymethyl
30 group.

Thus in a further aspect, the invention provides novel linkers of the formula (VIII). The linkers may also be

- 13 -

linked to other pharmaceutical compounds containing a free hydroxy, amino or mercapto group to provide novel prodrugs and such prodrugs form an additional aspect of the invention. The novel prodrugs may be prepared as pharmaceutical compositions and may be used in the treatment of patients using ADEPT or GDEPT as described herein.



To produce a compound of formula (VIII), optionally substituted 4-hydroxybenzaldehyde is protected as a 1,3-dithiane or dithiolane in an aprotic solvent such as CH_2Cl_2 in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$, at room temperature by reaction with 1,3-propanedithiol or 1,2-ethanedithiol, to give the corresponding 4(1',3'-dithianyl) phenol or 4(1',3'-dithidanyl) phenol. This compound is coupled with di- C_{1-6} alkyl-glutamyl isocyanate, in an aprotic solvent such as toluene in the presence of a tertiary organic amine such as triethylamine, to the corresponding O[4(1',3'-dithianyl)-phenyl]N(di- C_{1-6} alkyl-glutamyl)carbamate. The deprotection of the carbamate to the corresponding aldehyde, may be carried out with $\text{Hg}(\text{ClO}_4)_2$ or $\text{Tl}(\text{NO}_3)_3$ in THF or dichloromethane at room temperature. The reduction of the aldehyde yields the desired O(4-benzyl-oxy)N(di- C_{1-6} alkyl-glutamyl) carbamate. This may be deprotected by treatment with an acid such as trifluoroacetic or formic acid to remove the alkyl ester protecting groups to provide a prodrug of formula (V).

The novel linkers of formula (VIII) may be attached to PTKi compounds or other pharmaceutical compounds containing a free hydroxy, amino or mercapto group in the same way as described above for the linkers of formula (VII). Thus the invention further provides a compound which is a prodrug of an active drug wherein the active drug has at least one free amino, hydroxyl or mercapto group which is/are linked to one or more (e.g. from 1 to 5, e.g. 1, 2 or 3) linkers of the formulae (VII) or (VIII), each of which may be the same or different.

- 14 -

Other suitable PTKi prodrugs (including tyrphostins such as those of formula (I)) include those which are derivatized with a sugar or a β -lactam derivative. For example, suitable linkers which may be attached to PTK inhibitors of the type

5 PTK-NH₂ or PTK-OH or PTK-SH described above are:



where R is hydrogen or acetyl and Y is aryl such as phenyl, benzyl or tolulyl, and these may be made in an analogous manner to the other prodrugs described above.

Any hydroxy, amino or mercapto group of a PTKi may be linked

10 in the manner described above to provide a prodrug of the present invention. If desired, more than one such group may be derivatized to make a prodrug. If however only a single hydroxy, mercapto or amino group is to be reacted to form a prodrug, any remaining groups of the PTK may be protected

15 with for example tbutyl or adamantyl groups (in the case of hydroxyl) or butyloxycarbonyl groups in the case of amino. Such protecting groups may be attached using chemical processes known in the art. The groups of the PTKi to be reacted with the linker may be derivatized to the

- 15 -

corresponding haloformate or isocyanate and then coupled with the linkers such as those of formulae (VII) or (VIII). After the PTKi prodrug has been made, the protecting groups may be removed by conventional means, eg by treatment with trifluoroacetic acid.

Physiologically acceptable derivatives of said prodrug include salts, amides, esters and salts of esters. Esters include carboxylic acid esters in which the non-carbonyl moiety of the ester grouping is selected from straight or branched chain C_{1-6} alkyl, (methyl, n-propyl, n-butyl or t-butyl); or C_{3-6} cyclic alkyl (e.g. cyclohexyl). Salts include physiologically acceptable base salts, eg derived from an appropriate base, such as alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium) salts, ammonium and NR_4 (wherein R is C_{1-4} alkyl) salts. Other salts include acid addition salts, including the hydrochloride and acetate salts. Amides include non-substituted and mono- and di-substituted derivatives.

The invention further provides pharmaceutical formulations. Such formulations comprise a compound of the invention together with one or more pharmaceutically acceptable carriers or diluents.

Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral or parenteral (e.g. intramuscular or intravenous) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or

- 16 -

both, and then, if necessary, shaping the product.

For example, formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the polypeptide to blood components or one or more organs.

Suitable liposomes include, for example, those comprising the positively charged lipid (N[1-(2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA), those comprising dioleoyl-phosphatidylethanolamine (DOPE), and those comprising 3 β [(n',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol).

The PTKi prodrugs of the present invention and the antibody/enzyme conjugate for ADEPT can be administered simultaneously but it is often found preferable, in clinical practice, to administer the enzyme/agent conjugate before the prodrug, e.g. up to 72 hours or even 1 week before, in order to give the enzyme/agent conjugate an opportunity to localise in the region of the tumour target. By operating in this way, when the prodrug is administered, conversion of the prodrug to the cytotoxic agent tends to be confined to the regions where the enzyme/agent conjugate is localised, i.e. the region of the target tumour the premature release of the PTKi agent is minimised.

In VDEPT the prodrug will usually be administered following administration of the modified virus encoding an enzyme. Typically, the virus will be administered to the patient and then the uptake of the virus by infected cells monitored, for example by recovery and analysis of a biopsy sample of

- 17 -

targeted tissue. Similarly in GDEPT the prodrug will usually be administered following the administration of a delivery system containing the gene encoding the enzyme.

5 In ADEPT the degree of localisation of the enzyme/agent conjugate (in terms of the ratio of localized to freely circulating active conjugate) can be further enhanced using the clearance and/or inactivation systems described in WO89/10140. This involves, usually following administration of the conjugate and before administration of the prodrug,
10 the administration of a component (a "second component") which is able to bind to the such part of the conjugate so as to inactivate the enzyme and/or accelerate the clearance of the conjugate from the blood. Such a component may include an antibody to the enzyme component of the system which is
15 capable of inactivating the enzyme.

The second component may be linked to a macromolecule such as dextran, a liposome, albumin, macroglobulin or a blood group O erythrocyte so that the second component is restrained from leaving the vascular compartment. In addition or as an
20 alternative, the second component may include a sufficient number of covalently bound galactose residues, or residues of other sugars such as lactose or mannose, so that it can bind the conjugate in plasma but be removed together with the conjugate from plasma by receptors for galactose or other
25 sugars in the liver. The second component should be administered and designed for use such that it will not, to any appreciable extent, enter the extravascular space of the tumour where it could inactivate localised conjugate prior to and during administration of the prodrug.

30 The exact dosage regime for both GDEPT and ADEPT will, of course, need to be determined by individual clinicians for individual patients and this, in turn, will be controlled by the exact nature of the prodrug and the cytotoxic agent to be

- 18 -

released from the prodrug but some general guidance can be given. Chemotherapy of this type will normally involve parenteral administration of both the prodrug and either the enzyme/agent conjugate or modified virus and administration by the intravenous route is frequently found to be the most practical. In ADEPT systems, the dose of the prodrug and conjugate will ultimately be at the discretion of the physician, who will take into account such factors as the age, weight and condition of the patient. Suitable doses of prodrug and conjugate are given in Bagshawe et al. Antibody, Immunoconjugates, and Radiopharmaceuticals (1991), 4, 915-922. A suitable dose of conjugate may be from 500 to 200,000 enzyme units/m² (e.g. 20,000 enzyme units/m²) and a suitable dose of prodrug may be from 5 to 2000 mg/m² (e.g. 200 mg/m²).

In order to secure maximum concentration of the conjugate at the site of desired treatment, it is normally desirable to space apart administration of the two components by at least 4 hours. The exact regime will be influenced by various factors including the nature of the tumour to be targeted and the nature of the prodrug, but usually there will be an adequate concentration of the conjugate at the site of desired treatment within 48 hours.

In GDEPT systems, the amount of virus or other vector delivered will be such as to provide a similar cellular concentration of enzyme as in the ADEPT system mentioned above. This may be determined by clinical trials which involve administering a range of trial doses to a patient and measuring the degree of infection or transfection of a target cell or tumour. The amount of prodrug required will be similar to or greater than that for ADEPT systems.

The present invention also provides a system for use in the control of neoplasia in a human or animal subject comprising an enzyme capable of converting a PTKi prodrug to an active

- 19 -

PTKi, preferably conjugated with a targeting agent such as monoclonal antibody that will bind to a tumour-associated antigen, in association with a prodrug as defined above. When the enzyme is a nitroreductase, the system also preferably comprises a suitable cofactor for the enzyme. 5 Suitable cofactors include a riboside or ribotide of nicotinic acid or nicotinamide.

10 The present invention extends to a method of treating neoplasia in a human or animal subject requiring such treatment which comprises administering to the host an effective amount of a PTKi prodrug of the invention and an enzyme, preferably conjugated with a targeting agent such as a monoclonal antibody that will bind to a tumour-associated antigen.

15 The present invention also provides a system for use in the control of neoplasia in a human or animal subject comprising a modified virus or other delivery system capable of selectively infecting tumour cells in said subject, said virus carrying a DNA or RNA sequence encoding an enzyme, in 20 association with a PTKi prodrug capable of being converted to a PTKi by the action of said enzyme.

25 The present invention extends to a method of treating neoplasia in a human or animal subject requiring such treatment which comprises administering to the host an effective amount of a PTKi prodrug of the invention and a modified virus, said modified virus capable of selectively infecting tumour cells in said subject, said virus carrying a DNA or RNA sequence encoding an enzyme capable of converting said PTKi prodrug to an active PTKi.

30 The present invention also extends to a method of treating neoplasia in a human or animal subject requiring such treatment which comprises administering to the host an

- 20 -

effective amount of a PTKi prodrug of the invention and a non viral vector system, said non-viral vector system capable of being selectively introduced into tumour cells in said subject, said vector system carrying a DNA or RNA sequence encoding an enzyme capable of converting said PTKi prodrug to an active PTKi operably linked to a promoter effective in expressing said enzyme in said cells.

The various systems for use in the treatment of neoplasia by ADEPT described above optionally include the "second component" for accelerated clearance described above. Likewise, the methods of treatment of neoplasia described above optionally include as part of that method the use of the second component, an effective amount of which is administered after administration of the enzyme, in order to increase the ratio of localised to freely circulating enzyme. Reference may be made to WO89/10140 for further particular details of the second component, and such details can be incorporated for use in the present invention.

Modified viruses capable of selectively infecting tumour cells are known in the art. By "selectively infecting" it is meant that the virus will primarily infect tumour cells and that the proportion of non-tumour cells infected is such that the damage to non-tumour cells by administration of the PTKi prodrug will be acceptably low, given the nature of the disease being treated. Ultimately, this will be determined by the physician.

It will also be understood that the DNA or RNA sequence encoding an enzyme carried by the virus will be linked to suitable expression control signals such that expression of the enzyme will occur in the targeted tumour cells.

The non-viral vector system will be capable of being selectively introduced into tumour cells utilizing methods

- 21 -

such as those mentioned above, e.g. calcium phosphate co-precipitation, microinjection, liposomes, direct DNA uptake, and receptor-mediated DNA transfer (Morgan & French Anderson, *Annu. Rev. Biochem.*, 1993, 62;191).

- 5 Suitable monoclonal antibodies for use in the present invention include antibodies to cerbB2, such as ICR12 (Bakir, M A et al, *J. Nucl. Med* (1992) 33;2154-2160), and antibodies to epidermal growth factor receptor, such as ICR16 (Dean, CJ et al, *Int. J. Cancer Suppl.* 8, (1994), 103).
- 10 As used herein, the term "monoclonal antibody" will be understood by those of skill in the art not simply to refer to antibodies produced by traditional hybridoma techniques, but also to cover antibodies and variants thereof produced by recombinant means. These include, for example, humanised
- 15 antibodies such as those with a constant region from a human antibody grafted onto a non-human antibody variable region (see for example EP-A-O 120 694), chimeric antibodies such as those with non-human complementarity determining regions (CDRs) grafted into a human variable region framework (see
- 20 for example EP-A-O 239 400) and single chain antibodies. Fragments of such monoclonal antibodies which retain their target binding activity are also included by the general term "monoclonal antibody". This includes Fv, Fab' and F(ab')₂ fragments. It also includes recombinant or synthetic
- 25 proteins based upon the CDRs of such antibodies, e.g. abzymes (a polypeptide with both antibody-like binding activity and enzyme activity) and diabodies.

- Prodrugs of the present invention may also be used as reagents in in vitro systems to test the activity of
- 30 candidate enzymes or antibodies which may be incorporated into ADEPT or GDEPT systems.

- 22 -

For example, a tumour cell line carrying a marker to which an antibody is directed may be grown in vitro, and then an antibody-enzyme conjugate added to the culture. The enzyme will be one which is, or suspected to be, capable of converting a prodrug of the invention into an active drug. The prodrug is then added to the culture and the amount of cell killing or inhibition of cell growth is measured (for example by using a vital stain to record the number of viable cells or by replating a sample of the culture to count the number of viable cells).

Examples.

The following examples illustrate the invention. The reaction schemes which follow further illustrate these examples.

All starting materials, reagents and anhydrous solvents (THF under N_2) were purchased from Aldrich, unless otherwise stated. The di-tert-butyl glutamate is commercially available from Sigma. Kieselgel 60 (0.043-0.060) was used in gravity columns (Art 9385 and 15111, Merck). TLC was performed on precoated sheets of Kieselgel 60 F_{254} (Art 5735, Merck). Electron Impact spectra were determined with a VG 7070H mass spectrometer and a VG 2235 data system using the direct-insertion method, an ionizing energy of 70 eV, trap current of 100 mA and an ion-source temperature at 180-200 °C. FAB mass spectra were determined using xenon gas. High resolution accurate mass spectra were determined on the same systems. Reported spectra are by FAB unless otherwise stated. NMR spectra were determined in Me_2SO-d_6 on a Bruker AC250 spectrometer (250 MHz) at 30 °C (303 K) unless otherwise stated. I.R. spectra (film) were recorded on a Perkin Elmer 1720X FT-I.R. spectrometer.

Example 1.

- 23 -

Summary.

A tyrphostin prodrug, N¹(4-hydroxybenzyl)N³(di-tert-butyl-glutamyl) urea, 8 (See Scheme 1) cleavable by the enzyme CPG2 was made. This compound is designed to be coupled to the hydroxy, mercapto or amino functional groups of tyrphostin compounds. The intermediate N¹(4-hydroxybenzyl)N³(di-tert-butyl-glutamyl) urea 8, was synthesised for coupling to tyrphostin drugs according to the Scheme 1. The starting material, 4-nitrobenzylic alcohol, 1, was protected as tert-butyl-di-phenyl-silyl ether, 2, by reacting with tert-butyl-diphenyl-chlorosilane and imidazole in DMF (or THF) at room temperature. The protected nitro derivative, 2, was reduced by hydrogen transfer with ammonium formate (Pd/C 10% in EtOH). The amine, 3, thus formed was reacted with triphosgene in toluene at 70 °C, to form the corresponding isocyanate 4. The protected linker, 7, was obtained by coupling the isocyanate 4 with di-tert-butyl-glutamate in THF in the presence of NEt₃ at room temperature. An alternative route to 7 was by the direct coupling of amine 3 with the di-tert-butyl-glutamyl isocyanate 6, under the same conditions as described above, where the di-tert-butyl-glutamyl isocyanate 6 was obtained from the di-tert-butyl-glutamate by treatment with triphosgene and NEt₃ in toluene at -78 °C. Using this route, the compound 7 was obtained in good yield from the amine 3 and di-tert-butyl-glutamate in a one-pot synthesis.

The compound 7 was deprotected by Bu₄NF in THF at room temperature and the di-tert-butyl ester of the linker, 8, purified by column chromatography. The ester 8 was reacted with 4-chloroformyl-benzilydene-malononitrile, 10, resulting in the di-tert-butyl ester linker of the tyrphostin 11. A phase transfer catalysis system was utilised since the phosgenation of the 4-hydroxy-benzilydene-malononitrile 9, which would be the usual procedure of choice, resulted only in the corresponding carbonate. The phase transfer method

- 24 -

used tetra-butylammonium hydrogen sulphate as catalyst and led to a high yield of the desired compound. The final deprotection to compound 12 was carried out using formic acid at 4 °C.

5 Experimental.

(4-nitro-benzyl) tert-butyl-di-phenyl-silyl ether (2).

To a stirred solution of 4-nitrobenzyl alcohol, 1, (1.00 g, 6.50 mmol), and imidazole (0.97 g, 14.1 mmol) in DMF (10.0 mL), was added tert-butyl-diphenyl-chlorosilane (1.98 g, 7.20 mmol) over 10 min under N₂ at room temperature. The reaction mixture was stirred for an additional 5 h, diluted with Et₂O (75 mL), washed with H₂O (5 x 15 mL), dried (MgSO₄) and evaporated to dryness under vacuum. An oil was obtained which crystallised on standing and was recrystallised to a solid from EtOH (70%); yield: 2.36 g (93.%). v_{\max}/cm^{-1} (film): 2931, 2857 (CH₂, asym., sym.), 1521, 1345 (NO₂); ¹H-NMR, d_H: 1.06 (9H, s, t-Bu), 4.92 (2H, s, CH₂), 7.42-7.46 (5H, m, Ph), 7.63-7.65 (7H, m, Ph+H_{arom2+6}), 8.23 (2H, d, J = 8.23, H_{arom3+5}); MS, (EI), (391.54); m/z: 334 (M - t-Bu, 100), 288 (M - t-Bu - NO₂, 10), 256 (M - t-Bu - Ph, 20), 199 (Ph₂SiOH⁺, 100); C₂₃H₂₅NO₃Si.

(4-amino-benzyl) tert-butyl-di-phenyl-silyl ether (3)

To a stirred solution of 2 (5.00 g, 12.77 mmol) in ethanol (100 mL) was added Pd/C (10%, 1.50 g) and ammonium formate (4.60 g) at room temperature. After 1.5 h the catalyst was removed by filtration, the filtrate concentrated to dryness under vacuum and the residue partitioned between EtOAc:H₂O. The organic layer was dried (MgSO₄) and concentrated under vacuum to give 3 as an oil; yield: 4.24 g (92 %); v_{\max}/cm^{-1} (film): 3433, 3378 (NH₂), 2931, 2857 (CH₂, asym., sym.); ¹H-NMR, d_H: 1.00 (9H, s, t-Bu), 4.57 (2H, s, CH₂), 4.98 (2H, s

- 25 -

broad, NH₂), 6.52 (2H, d, J = 8.25, H_{arom3+5}), 6.96 (2H, d, H_{arom2+6}), 7.42-7.46 (5H, m, Ph), 7.62-7.65 (5H, m, Ph); MS, (EI), (361.56); m/z: 361 (M⁺, 8), 304 (M - t-Bu, 100), 199 (Ph₂SiOH⁺, 100); C₂₃H₂₇NOSi.

5 (4-isocyanato-benzyl)tert-butyl-di-phenyl-silyl ether (4)

To a stirred solution of 3 (0.63 g, 1.70 mmol) and triethylamine (0.16 g, 0.60 mmol) in toluene (10 mL) at 70 °C, was added triphosgene (0.18 g, 1.7 mmol). After 5 h the reaction mixture was filtered and the filtrate evaporated to an oil under vacuum; yield: 0.65 g (99 %) which was used without further purification; $\nu_{\max}/\text{cm}^{-1}$ (film): 2931, 2857 (CH₂, asym., sym.), 2275 (NCO); ¹H-NMR, d_H: 1.03 (9H, s, t-Bu), 4.76 (2H, s, CH₂), 7.23 (2H, d, J = 8.38, H_{arom3+5}), 7.35 (2H, d, H_{arom2+6}), 7.37-7.48 (5H, m, Ph), 7.62-7.71 (5H, m, Ph); MS, (EI), (387.55); m/z: 330 (M - t-Bu, 52), 286 (M - t-Bu, M - t-Bu - NCO, 48), 199 (Ph₂SiOH⁺, 100); C₂₄H₂₅NO₂Si.

N¹(4-tert-butyl-di-phenyl-silyl-O-benzyl)N³(di-t-butyl-glutamyl) urea (7)

Method A: To a solution of di-tert-butyl-glutamate hydrochloride (0.46 g, 1.55 mmol) in THF (7 mL) was added triethylamine (0.31 g 3.10 mmol). The isocyanate, 4, (0.60 g, 1.55 mmol) in dry THF (3 mL) was added to the glutamate ester at room temperature. After 2 h the reaction mixture was filtered and evaporated to dryness under vacuum. The product was purified by column chromatography (EtOAc : cyclohexane 2:1) resulting in the oil, 7; yield 0.53 g (53%). $\nu_{\max}/\text{cm}^{-1}$ (film): 3359 (NH), 2932, 2857 (CH₂, asym., sym.), 1729 (C=O, ester), 1670 (C=O, urea), 1154 (C-O, str.); ¹H-NMR, d_H: 1.03 (9H, s, t-Bu), 1.40 (9H, s, t-Bu-glu), 1.43 (9H, s, t-Bu-glu), 1.68-2.00 (2H, 2m, CH(NH)CH₂), 2.18-2.32 (2H, 2m, CH₂CO₂-t-Bu), 4.08-4.12 (1H, m, CH(NH)CH₂), 4.68 (2H, s, CH₂), 6.38 (1H, d, J = 8.12, NH-glu), 7.19 (2H, d, J = 8.41,

- 26 -

$H_{\text{arom}3+5}$), 7.32-7.47 (7H, m, $\text{Ph}+H_{\text{arom}2+6}$), 7.62-7.70 (5H, m, Ph), 8.54 (1H, s, NH-Ph); MS, (EI), (646.90); m/z: 540 (M - t-Bu + 1, 2), 534 (M - 2t-Bu + 2, 5), 478 (M - 3t-Bu + 3, 100), 199 (Ph_2SiOH^+ , 100); $\text{C}_{37}\text{H}_{50}\text{N}_2\text{O}_6\text{Si}$.

5 Method B: (one pot synthesis of compound 7) To a solution of di-tert-butyl-glutamate hydrochloride (4.14 g, 14.0 mmol) and triphosgene (1.39 g, 4.67 mmol) in toluene at -78°C , triethylamine (2.83 g, 28.0 mmol) in toluene (10 mL) was added dropwise over 30 min. The reaction was allowed to warm
10 to room temperature. After 50 min, a solution containing (4-amino-benzyl)tert-butyl-diphenyl-silyl ether, 3 (5.00 g, 13.8 mmol) and triethylamine (1.95 mL, 14.0 mmol) was added over 5-10 min. After 20 h, the reaction mixture was filtered, washed sequentially with: H_2O (200 mL), aq HCl (1%, 200 mL),
15 aq Na_2CO_3 (1%, 200 mL), H_2O (2 x 200 mL) dried (Mg_2SO_4) and evaporated to an oil under vacuum; yield: 9.90 g. This product was deprotected without further purification.

$\text{N}^1(4\text{-hydroxybenzyl})\text{N}^3(\text{di-tert-butyl-glutamyl})\text{urea (8)}$

From Method A- To a solution of 7, (0.53 g, 0.80 mmol) in THF
20 (10 mL) was added tetra-butylammonium fluoride (2.5 mL, 2.5 mmol of 1M solution) in THF at room temperature. After 3 h, the reaction mixture was evaporated to dryness under vacuum. The product was dissolved in EtOAc (20mL), washed with H_2O (2 x 10 mL), dried (MgSO_4) and evaporated to an oil; yield: 0.40
25 g.

The deprotected compound, 8 (0.38 g), was purified by column chromatography (EtOAc : cyclohexane 3:1) resulting in an oil which crystallised on standing; yield 0.093 g (29.%). $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3370 (broad, NH+OH), 2967 (CH_3), 2930, 2857 (CH_2 , asym., sym.), 1716 (C=O, ester), 1678 (C=O, urea), 1153 (C-O, str.); $^1\text{H-NMR}$, d_H : 1.40 (9H, s, t-Bu), 1.42 (9H, s, t-Bu),
30 1.72-2.00 (2H, 2m, $\text{CH}(\text{NH})\text{CH}_2$), 2.20-2.31 (2H, 2m, $\text{CH}_2\text{CO}_2\text{-t-Bu}$), 4.10-4.18 (1H, m, $\text{CH}(\text{NH})\text{CH}_2$), 4.39 (2H, d, $J = 5.36$,

- 27 -

CH₂), 4.99 (1H, t, CH₂OH), 6.38 (1H, d, J = 8.11, NH-glu), 7.16 (2H, d, J = 8.35, H_{arom3+5}), 7.31 (2H, d, H_{arom2+6}), 8.50 (1H, s, NH-Ph); MS, (EI), (408.94); m/z: 408 (M⁺, 10), 352 (M - t-Bu + 1, 4), 296 (M - 2t-Bu + 2, 14); C₂₁H₃₂N₂O₆.

- 5 From Method B- The one pot procedure yielded 8, which was purified by column chromatography; yield 2.57 g (46% over three steps) which was recrystallised from aq MeOH (60%).

(4-chloroformyl-benzylidene) malononitrile (10)

- 10 The Na salt of 4-chloroformyl-benzylidene malononitrile, 9 (0.34 g, 2.0 mmol), was made in aq NaOH (10 mL, 0.10 g, 2.5 mmol). To this solution was added the phase transfer catalyst, tetra-butyl ammonium hydrogen sulphate (0.070 g, 0.2 mmol) in CH₂Cl₂ (8mL) with vigorous stirring. To this was
15 added a solution of phosgene (20%, 0.40 g, 4.0 mmol) in toluene at room temperature. After 30 min the organic layer was separated, washed with H₂O, dried (MgSO₄) and evaporated to a solid under vacuum; yield: 0.39 g (84%). $\nu_{\max}/\text{cm}^{-1}$ (film): 2230 (CN), 1784 (C=O, chloroformate), 1199, 1166 (C-O, str.);
20 ¹H-NMR, (CDCl₃), δ_{H} : 7.50 (2H, d, J = 8.81, H_{arom3+5}), 7.79 (1H, s, H_{vinyl}), 8.02 (2H, d, H_{arom2+6}); MS, (EI), (232.63); m/z: 232 (M⁺, 100); C₁₁H₅N₂O₂Cl.

N¹[(4-benzylidene-malononitrile-oxy-carbonyl)-4-oxybenzyl)]N³(di-tert-butyl-glutamyl) urea (11)

- 25 To a solution of 10 (1.5 mmol) in CH₂Cl₂ (10 mL) was added N¹(4-hydroxybenzyl)N³(di-t-butyl-glutamyl) urea, 8 (0.41 g, 1.0 mmol) in dry THF (12.5 mL) and triethylamine (0.25 mL, 1.65 mmol) at room temperature under N₂. After 22 h, the reaction mixture was evaporated to a volume of 5 mL, dissolved in EtOAc (20 mL), washed sequentially with H₂O (2
30 x 20 mL), aq NaOH (1%, 20 mL), H₂O (2 x 20 mL), dried (MgSO₄)

- 28 -

and evaporated under vacuum to an oil which was purified by column chromatography (EtOAc : cyclohexane 3:1) resulting in a solid; yield 0.28 g (65%) (0.12 g of the starting material 8 was recovered). $\nu_{\max}/\text{cm}^{-1}$ (film): 3369 (NH), 2924, 2857 (CH_2 , asym., sym.), 1765 (C=O, carbonate), 1728 (C=O, ester), 1658 (C=O, urea), 1216, 1153 (C-O, str.); $^1\text{H-NMR}$, d_H : 1.40 (9H, s, t-Bu), 1.43 (9H, s, t-Bu), 1.80-2.00 (2H, 2m, $\text{CH}(\text{NH})\text{CH}_2$), 2.22-2.35 (2H, 2m, $\text{CH}_2\text{CO}_2\text{-t-Bu}$), 4.10-4.20 (1H, m, $\text{CH}(\text{NH})\text{CH}_2$), 5.21 (2H, s, CH_2), 6.46 (1H, d, $J = 8.10$, NH-glu), 7.33 (2H, d, $J = 8.48$, $H_{\text{arom3+5-cmpd 8}}$), 7.42 (2H, d, $H_{\text{arom2+6-cmpd 8}}$), 7.53 (2H, d, $J = 8.67$, $H_{\text{arom3+5-cmpd 9}}$), 8.02 (2H, d, $H_{\text{arom2+6-cmpd 9}}$), 8.54 (1H, s, NH-Ph), 8.68 (1h, s, H_{vinyl}); MS, (604.59); m/z : 391 (M - 169 - CO_2 , 2), 279 (M - 169 - CO_2 - 2t-Bu + 2, 30) (169 = cmpd 9 - 1); $\text{C}_{32}\text{H}_{36}\text{N}_4\text{O}_8$.

15 $\text{N}^1[(4\text{-benzylidene-malononitrile-oxy-carbonyl})\text{-4-oxybenzyl}]\text{N}^3\text{glutamyl urea (12)}$

Compound, 11 (0.05 g, 0.08mmol) was dissolved in formic acid (95%, 6.0 mL), at 4 °C under N_2 . After 22 h the solvent was evaporated under vacuum (pump) to give a solid; yield: 0.037 g (91%). $\nu_{\max}/\text{cm}^{-1}$ (film): 3370 (v. broad, NH+OH), 2930, 2857 (CH_2 , asym., sym.), 1719 (C=O, ester), 1681 (C=O, urea), 1221, 1176 (C-O, str.); $^1\text{H-NMR}$, d_H : 1.80-2.10 (2H, 2m, $\text{CH}(\text{NH})\text{CH}_2$), 2.20-2.35 (2H, 2m, $\text{CH}_2\text{CO}_2\text{H}$), 4.20-4.30 (1H, m, $\text{CH}(\text{NH})\text{CH}_2$), 5.07 (2H, s, CH_2), 6.47 (1H, d, $J = 7.86$, NH-glu), 6.80 (2H, d, $J = 8.76$, $H_{\text{arom3+5-cmpd 9}}$), 7.25 (2H, d, $J = 8.39$, $H_{\text{arom3+5-cmpd 8}}$), 7.39 (2H, d, $H_{\text{arom2+6-cmpd 8}}$), 7.89 (2H, d, $H_{\text{arom2+6-cmpd 9}}$), 8.29 (1H, s, NH-Ph), 8.69 (1h, s, H_{vinyl}); MS, (492.44); m/z : 323 (M - 169, 18), 277 (M - 169 - CO_2 , 18) (169 = cmpd 9 - 1); $\text{C}_{24}\text{H}_{20}\text{N}_4\text{O}_8$.

30 Example 2.

Summary.

- 29 -

Two tyrphostin prodrugs were designed which could be activated by the enzyme nitroreductase. These are 4(4-nitro-phenyl-oxy-carbonyl)oxy-benzylidene-malononitrile, 15a, and 3,4-di(4-nitro-phenyl-oxy-carbonyl)oxy-benzylidene-malononitrile, 15b, (See Scheme 2). For these syntheses, 4-hydroxy-benzylidene-malononitrile, 13a, and 3,4-dihydroxy-benzylidene-malononitrile, 13b were coupled with 4-nitrobenzyl-chloroformate 14, leading to the desired prodrugs, 15a and 15b respectively.

Experimental.

4(4-nitro-phenyl-oxy-carbonyl)oxy-benzylidene-malononitrile (15a).

To a solution of 4-hydroxy-benzylidene-malononitrile, 13a (0.50 g, 2.93 mmol), in dry THF (10 mL), was added 4-nitrobenzyl chloroformate, 14 (0.63 g, 2.92 mmol) and triethylamine (0.30 g, 3.0 mmol) at an initial temperature of 4 °C. After 2.5 h, the reaction mixture was filtered and the filtrate evaporated to dryness under vacuum. The residue thus obtained was partitioned against EtOAc : H₂O (1:1, 25 mL), the organic layer washed sequentially with aq NaOH (2%, 25 mL), aq HCl (2%, 25 mL) and H₂O (2 x 25 mL), dried (MgSO₄) and evaporated to a solid under vacuum; yield: 0.55 g (54.%), which was recrystallised from EtOH. $\nu_{\max}/\text{cm}^{-1}$ (film): 2230 (CN), 1767 (C=O, carbonate), 1522, 1349 (NO₂), 1221 (C-O, str.); ¹H-NMR, δ_{H} : 5.46 (2H, s, CH₂), 7.55 (2H, d, J = 8.77, H_{arom3+5}), 7.73 (2H, d, J = 8.70, H_{arom2+6}-PhNO₂), 8.03 (2H, d, H_{arom2+6}), 8.27 (2H, d, H_{arom3+5}-PhNO₂), 8.55 (1H, s, H_{vinyl}); MS, (EI), (349.30); m/z: 349 (M⁺, 3), 305 (M-CO₂, 60); C₁₈H₁₁N₃O₅.

3,4-di(4-nitro-phenyl-oxy-carbonyl)oxy-benzylidene-malononitrile (15b)


- 30 -

A similar procedure was used for 3,4-di-hydroxy-benzylidene-malononitrile, 13b (0.50 g, 2.70 mmol) resulting in a solid; yield: 0.86 g, (59.%) which was recrystallised from EtOH. v_{\max}/cm^{-1} (film): 2232 (CN), 1776 (C=O, carbonate), 1523, 1350 (NO₂), 1247 (C-O, str.); ¹H-NMR, d_H : 5.44 (4H, s, CH₂), 7.66 (4H, d, J = 8.65, H_{arom2+6}-2PhNO₂), 7.79 (1H, d, J = 8.40, H_{arom5}), 7.99 (1H, q, H_{arom6}), 8.01 (1H, d, H_{arom2}), 8.18 (2H, d, H_{arom3+5}-PhNO₂'), 8.19 (2H, d, H_{arom3+5}-PhNO₂''), 8.56 (1H, s, H_{vinyl}).

10 Example 3.


Summary and Experimental.

O(4-hydroxybenzyl)N(di-tert-butyl-glutamyl) carbamate, 20 (See Scheme 3), another self-immolative linker, was prepared. Compound 16, 4-hydroxy-benzaldehyde, was protected with 1,3-propane-dithiol in CH₂Cl₂ in the presence of BF₃.Et₂O, at room temperature, to give the 4(1',3'-dithianyl) phenol, 17, in good yield. Coupling of 17 with di-tert-butyl-glutamyl isocyanate, 6, in toluene in the presence of Et₃N, led to the O[4(1',3'-dithianyl)-phenyl]N(di-tert-butyl-glutamyl)carbamate, 18. The deprotection of the carbamate, 18, to the corresponding aldehyde, 19, was carried out with Hg(ClO₄)₂ in THF at room temperature. The reduction of 19 yielded the desired O(4-benzyl-oxy)N(di-tert-butyl-glutamyl) carbamate, 20. This is coupled to the tyrphostin of 10 as described above in Example 1 and the ester protecting groups are removed.




SCHEME 1

- 32 -

a: THF, NEt₃, 20°.

SCHEME 2

- 33 -




SCHEME 3

- 34 -

CLAIMS

1. A compound which comprises a prodrug of a protein tyrosine kinase inhibitor (PTKi) linked to at least one protecting group said group being capable of being cleaved from said compound to release the protein tyrosine kinase inhibitor or a physiologically acceptable derivative of said prodrug.
2. A compound according to claim 1 wherein the PTKi is a tyrphostin, a flavonoid, erbstatin, a benzoquinoid ansamycin antibiotic, a peptide or analogue thereof, or a nucleotide or analogue thereof.
3. A compound according to claim 2 wherein the tyrphostin is of the formula (I)




where X represents carbon, a nitrogen or a group $N \rightarrow O$,
n is an integer from 1 to 3;
each group R^1 , which may be the same or different is
hydrogen, hydroxy, mercapto, carboxy, formyl, C_{1-4} alkyl,
 C_{2-4} alkenyl, C_{1-4} alkoxy, C_{1-4} alkylthio, carboxy C_{1-4} alkyl,
carboxy C_{2-4} alkenyl, C_{1-4} alkylsulphoxy, halo (ie. fluoro,
chloro, bromo or iodo), nitro, amino, C_{1-4} alkylamino, or
 C_{1-4} dialkylamino, or when n is 2 or 3 two R^1 groups may
together form a methylenedioxy or ethylenedioxy group;
 R^2 is hydrogen, hydroxy, C_{1-4} alkyl or together with

- 35 -


position 2 of the ring to which the group(s) R^1 is(are) attached forms a 5 or 6 membered aliphatic or heterocyclic ring, said 5 or 6 membered ring optionally containing a ketone group; and R^3 is cyano, carboxy, carbamoyl, thiocarbamoyl, a group $C(O)HNCH_2CN$, a group $C(NH_2)=C(CN)_2$, an alpha keto group $C(O)R^4$ where R^4 is 3,4-dihydroxyphenyl or 2-thiophenyl or an alpha amido group $C(O)NHR^5$ where R^5 is benzyl, phenyl or 2,4-dimethoxyphenyl; provided that at least one of the groups R^1 and R^2 are mercapto, hydroxy or amino.

4. A compound according to any one of claims 1 to 3 of the formula (II):




where X which may be the same or different is NH, O or S, m is an integer from 1 to 5, Ph which when m is from 2 to 5 may be the same or different is an optionally substituted phenylene ring and PTK is a group such that $PTK-(XH)_m$ is a PTKi containing m -XH groups, and wherein the nitro group is in the 2- or 4-position of the Ph ring.

5. A compound according to claim 4 of the formula (III):



where m is an integer from 1 to 5, Ph which when m is from 2 to 5 may be the same or different is an optionally substituted phenylene ring and PTK is a group such that $PTK-(OH)_m$ is a PTKi compound containing m hydroxyl groups, and wherein the nitro group is in the 2- or 4-position of the Ph ring.


6. A compound according to any one of claims 1 to 3 of the formula (V):



where X, which may be the same or different, is NH, O or


- 36 -

S, m is an integer from 1 to 5, PTK is the residue of a PTKi compound such that $\text{PTK}-(\text{XH})_m$ is a PTKi compound containing m -XH groups, Ph which when m is from 2 to 5 may be the same or different is an optionally substituted phenyl group, Z is -O.CO- or -NH.CO- and glu is the residue of glutamic acid of the formula:




or a di- C_{1-6} alkyl ester (e.g. an ethyl or t-butyl ester) thereof.

7. A compound according to claim 6 of the formula (VI):




where m is an integer from 1 to 5, PTK is the residue of a PTKi compound such that $\text{PTK}-(\text{OH})_m$ is a PTKi containing m hydroxy groups, Ph which when m is from 2 to 5 may be the same or different is an optionally substituted phenyl group, Z is -O.CO- or -NH.CO- and glu is the residue of glutamic acid of the formula:




or a di- C_{1-6} alkyl ester (e.g. an ethyl or t-butyl ester) thereof.

8. A compound of the formula (VII):




where Ph is an optionally substituted phenyl group and glu is the residue of glutamic acid of the formula:




or a di- C_{1-6} alkyl ester thereof, and wherein the optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the hydroxymethyl group.

9. A compound of the formula (VIII):



where Ph is an optionally substituted phenyl group and glu is the residue of glutamic acid of the formula:

- 37 -



or a di-C₁₋₆ alkyl ester thereof, and wherein the optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the hydroxymethyl group.

10. A compound according to any one of claims 4 to 9 wherein the phenylene ring (Ph) is substituted with 1 to 4 groups which may be the same or different which are selected from fluorine, chlorine, bromine, iodine, hydroxy, mercapto, amino, nitro, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and C₂₋₄ haloalkenyl.
11. A compound according to claim 10 wherein the ring is substituted at one or more of the 2-, 3-, 5- and/or 6-positions with fluorine.
12. A compound selected from the group consisting of:
N¹[(4-benzylidene-malononitrile-oxy-carbonyl)-4-oxybenzyl]N³(di-tert-butyl-glutamyl) urea;
N¹[(4-benzylidene-malononitrile-oxy-carbonyl)-4-oxybenzyl]N³glutamyl urea;
4(4-nitro-phenyl-oxy-carbonyl)oxy-benzylidene-malononitrile; and
3,4-di(4-nitro-phenyl-oxy-carbonyl)oxy-benzylidene-malono nitrile;
or a salt or ester thereof.
13. A compound selected from the group consisting of:
N¹(4-hydroxybenzyl)N³(di-tert-butyl-glutamyl) urea; and
O(4-benzyl-oxy)N(di-tert-butyl-glutamyl) carbamate.
14. A composition comprising a compound according to any one of claims 1 to 13 together with one or more pharmaceutically acceptable carriers or diluents.


- 38 -

15. A system for use in the control of neoplasia in a human or animal subject comprising:
- (i) an enzyme capable of converting a compound according to any one of claims 1 to 7 or 12 to an active drug conjugated with a targeting agent capable of binding to a tumour-associated antigen; and
 - (ii) a compound according to any one of claims 1 to 9 or 14.
16. A system for use in the control of neoplasia in a human or animal subject comprising
- (i) a modified virus capable of selectively infecting tumour cells in said subject, said virus carrying a DNA or RNA sequence encoding an enzyme, and
 - (ii) a compound according to any one of claims 1 to 7 or 12 capable of being converted to an active drug by the action of said enzyme.
17. A system according to claim 15 or 16 wherein the enzyme is a bacterial nitroreductase or a carboxypeptidase.
18. A compound comprising a prodrug of an active drug linked to one or more protecting groups said group being capable of being cleaved from said compound to release the active drug, wherein the active drug has at least one free amino, hydroxyl or mercapto group, and wherein each protecting group is:
- (i) of the formula:
$$-\text{OCO.O.CH}_2\text{-Ph-NH-CO-NH-glu}$$
where Ph, which may be the same or different, is an optionally substituted phenyl group and glu is the residue of glutamic acid of the formula:
$$-\text{CH}(\text{CO}_2\text{H})(\text{CH}_2\text{CH}_2\text{CO}_2\text{H})$$
or a di-C₁₋₆ alkyl ester thereof, and wherein the optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to

- 39 -


the oxycarbonyl group; or

(ii) of the formula:



where Ph and glu are as defined above, and wherein the optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the oxycarbonyl group;
or a physiologically acceptable derivative of said prodrug.

19. A process for the production of a compound of the formula $\text{PTKi}-(\text{PRT})_m$ where PTKi is a tyrphostin of formula (I):



where X represents carbon, a nitrogen or a group $\text{N}=\text{O}$,
n is an integer from 1 to 3;
each group R^1 , which may be the same or different is hydrogen, hydroxy, mercapto, carboxy, formyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{1-4} alkoxy, C_{1-4} alkylthio, carboxy C_{1-4} alkyl, carboxy C_{2-4} alkenyl, C_{1-4} alkylsulphoxy, halo (ie. fluoro, chloro, bromo or iodo), nitro, amino, C_{1-4} alkylamino, or C_{1-4} dialkylamino, or when n is 2 or 3 two R^1 groups may together form a methylenedioxy or ethylenedioxy group;
 R^2 is hydrogen, hydroxy, C_{1-4} alkyl or together with position 2 of the ring to which the group(s) R^1 is(are) attached forms a 5 or 6 membered aliphatic or heterocyclic ring, said 5 or 6 membered ring optionally containing a ketone group; and

- 40 -

R³ is cyano, carboxy, carbamoyl, thiocarbamoyl, a group C(O)HNCH₂CN, a group C(NH₂)=C(CN)₂, an alpha keto group C(O)R⁴ where R⁴ is 3,4-dihydroxyphenyl or 2-thiophenyl or an alpha amido group C(O)NHR⁵ where R⁵ is benzyl, phenyl or 2,4 dimethoxyphenyl

provided that at least one of the groups R¹ and R² are mercapto, hydroxy or amino;


m is an integer from 1 to 5;

and PRT which may be the same or different when m is from 2 to 5 is a protecting group capable of being cleaved from the tyrphostin by the action of an enzyme; wherein the tyrphostin is linked to the group PRT via said at least one mercapto, hydroxy or amino group; said process comprising:


reacting said protecting groups or precursor thereof with a tyrphostin of formula (I) under conditions which produce a compound of formula PTKi-(PRT)_m.

20. A process according to claim 19 wherein the protecting group is:

(i) of the formula:




where Ph is an optionally substituted phenyl group and glu is the residue of glutamic acid of the formula:



or a di-C₁₋₆ alkyl ester thereof, and wherein the optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the oxycarbonyl group; or

(ii) of the formula:



where Ph and glu are as defined above, and wherein the optionally substituted phenylene group is substituted at the 4-position by the glu-containing moiety relative to the oxycarbonyl group.

- 41 -

21. A process according to claim 20 wherein the compound produced is as defined in any one of claims 1 to 7 or 12.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48, 31/275		A3	(11) International Publication Number: WO 95/02420
			(43) International Publication Date: 26 January 1995 (26.01.95)
(21) International Application Number: PCT/GB94/01532		(81) Designated States: AU, CA, HU, JP, KR, NZ, US; European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 15 July 1994 (15.07.94)			
(30) Priority Data: 9314703.1 15 July 1993 (15.07.93) GB 9314702.3 15 July 1993 (15.07.93) GB		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71)(72) Applicants and Inventors: SPRINGER, Caroline, Joy [GB/GB]; The Institute of Cancer Research, The Royal Marsden Hospital, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 2NG (GB). MARAIS, Richard [GB/GB]; Chester Beatty Laboratories, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB (GB).		(88) Date of publication of the international search report: 16 March 1995 (16.03.95)	
(74) Agents: BRASNETT, Adrian, Hugh et al.; J.A. Kemp & Co, 14 South Square, Gray's Inn, London WC1R 5LX (GB).			

(54) Title: PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS

(57) Abstract

A compound which comprises a prodrug of a protein tyrosine kinase inhibitor (PTKI) linked to a protecting group, said group being capable of being cleaved from said compound to release the protein tyrosine kinase inhibitor. Protein tyrosine kinase inhibitors include tyrphostins, preferably those of formula (I), where X represents carbon, a nitrogen or a group N→O, n is an integer from 1 to 3; each group R¹, which may be the same or different is hydrogen, hydroxy, mercapto, carboxy, formyl, C₁₋₄alkyl, C₂₋₄ alkenyl, C₁₋₄alkoxy, C₁₋₄alkylthio, carboxy, C₁₋₄alkyl, carboxyC₂₋₄ alkenyl, C₁₋₄alkylsulphoxy, halo (i.e. fluoro, chloro, bromo or iodo), nitro, amino, C₁₋₄alkylamino, or C₁₋₄dialkylamino, or when n is 2 or 3 two R¹ groups may together form a methylenedioxy or ethylenedioxy group; R² is hydrogen, hydroxy, C₁₋₄alkyl or together with position 2 of the ring to which the group(s) R¹ is (are) attached forms a 5 or 6 membered aliphatic or heterocyclic ring, said 5 or 6 membered ring optionally containing a ketone group; and R³ is cyano, carboxy, carbamoyl, thiocarbamoyl, a group C(O)HNCH₂CN, a group C(NH₂)=C(CN₂), an alpha keto group C(O)R⁴ where R⁴ is 3,4-dihydroxyphenyl or 2-thiophene or an alpha amido group C(O)NHR⁵ where R⁵ is benzyl, phenyl, or 2,4-dimethoxyphenyl; provided that at least one of the groups R¹ and R² are mercapto, hydroxy or amino.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/GB 94/01532

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48 A61K31/275

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOCHEMISTRY (USA), 1989, VOL. 28, NO. 13, PAGE(S) 5694-5701, Saperstein R. et al 'Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells' see abstract see page 5695, left column see figure 1 see page 5696, left column see page 5699, right column - page 5700 --- -/--	1-5, 10, 14-19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

10 November 1994

Date of mailing of the international search report

2. 02. 95

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

DULLAART A.W.M.

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/GB 94/01532

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. LEUKOCYTE BIOL. (USA), 1993, VOL. 53, NO. 1, PAGE(S) 53-60, Dong Z. et al 'Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity' see abstract see "RESULTS" see "DISCUSSION" ---	1-5,10, 14-19
X,Y	DATABASE WPI Section Ch, Week 9315, Derwent Publications Ltd., London, GB; Class B02, AN 93-121272 & JP,A,5 058 894 (KANEKA CORP) 9 March 1993 see abstract & PATENT ABSTRACTS OF JAPAN vol. 17, no. 367 (C-1082) 12 July 1993 see abstract ---	1-5,10, 14-19
X,Y	EP,A,0 211 363 (KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA) 25 February 1987 see claims; figures; examples; tables ---	1-5,10, 14-19
Y	CANCER INVEST. (USA), 1991, VOL. 9, NO. 5, PAGE(S) 553-562, Ennis B.W. et al 'The EGF receptor system as a target for antitumor therapy' see page 560, left column ---	1-5,10, 14-19
Y	WO,A,91 16892 (RORER INTERNATIONAL , INC.) 14 November 1991 see claims; figures; examples ---	1-5,10, 14-19
Y	DATABASE WPI Section Ch, Week 9149, Derwent Publications Ltd., London, GB; Class B05, AN 91-354341 & CA,A,2 012 634 (UNIV BRIT COLUMBIA) 20 September 1991 see abstract & CHEMICAL ABSTRACTS, vol. 117, no. 3, 1992, Columbus, Ohio, US; abstract no. 20509, H. SALARI 'Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases' page 92 ; see abstract & DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US AN=117:020509 see abstract --- -/--	1-5,10, 14-19

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/GB 94/01532

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. CHEM. SOC., PERKIN TRANS. 2; 1992; NO. 7; PAGE(S) 1145-50 Mitchell A G et al 'Prodrugs of phosphonoformate: the effect of para-substituents on the products, kinetics and mechanism of hydrolysis of dibenzyl methoxycarbonylphosphonate' see "Results and Discussion" ---	1-5, 10, 14-19
Y	J. ORG. CHEM.; 1992; VOL. 57, NO. 6; PAGE(S) 1702-6 Getz J J et al 'Mechanism of hydrolysis of benzamidomethyl derivatives of phenols and its implications for prodrug design' see schemes see figures; tables ----	1-5, 10, 14-19
P, X	CANCER RES. (US), 15-05-1994, VOL. 54, NO. 10, PAGE(S) 2591-2597, Haimovitz-Friedman A. et al 'Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis' see the whole document -----	1-5, 10-12, 14-19

INTERNATIONAL SEARCH REPORT

I national application No.

PCT/GB94/01532

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please see attached sheet ../..
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please see attached sheet ../..

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7, 10-12, 14-21 in part

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB94/01532

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

LACK OF UNITY OF INVENTION

1. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of a tyrphostin structure.
2. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of a flavonoid structure.
3. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of erbstatin.
4. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of a benzoquinoid structure.
5. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of ansamycin.
6. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of a peptide structure.
7. Claims: 1-7,10-12,14-21 in part: relating to prodrugs of a nucleotide structure.
8. Claims: 8-9,13: A compound according to these claims.

The problem underlying the present application is, in its broadest form, the provision of new prodrugs, that can be used in the treatment of certain types of cancer, acting through the inhibition of the enzyme tyrosine kinase.

As solution to this problem, seven types of inhibitors of tyrosine kinase are used: see claim 2.

The special technical feature, linking these solutions together, is the use of a prodrug of a tyrosine kinase inhibitor in cancer therapy.

The use of prodrugs of inhibitors of tyrosine kinase and their prodrugs in cancer therapy is known: see Biochemistry, pages 5694-5701 (passages cited in the search report).

For this reason, the special-technical feature mentioned above can no longer be accepted as technical feature linking the different inventions together. A possible technical feature linking the different prodrugs together is to be found in the structure of the inhibitor.

In principal, each and every possible prodrug of a tyrosine kinase inhibitor forms a separate invention on its own. However, 7 (seven) groups of compounds can be indicated, based on structural elements, i.e. the structure of the inhibitor of tyrosine kinase, giving rise to the subjects as mentioned.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB94/01532

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Further, a separate group of compounds is given in claims 8, 9 and 13.

These compounds are not prodrugs of a tyrosine kinase inhibitor. No link with the previously mentioned compounds could be found, and thus form a separate subject a priori.

Since searching this plurality of different subjects would have caused major additional searching efforts, a search was performed for the first subject only.

It is to be noted, that each of the subjects not searched may, after the retrieval of new documents, give rise to further objections for lack of unity.

MEANINGFUL SEARCH NOT POSSIBLE OR INCOMPLETE SEARCH

OBSCURITIES, ETC.

In view of the large number of compounds, which are defined by the general definitions of the compounds to be used, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application (see guidelines, Part B, Chapter III, paragraph 3.6). Due to the unspecific definitions of ADEPT and VDEPT in both the claims and the description, the search relating to these techniques was performed only in relationship with the prodrug, for the same reasons of economy.

Partially searched claims	: 1-5,10-12,14-19
Completely searchable claims	: 8-9,13
Partially searchable claims	: 1-7,10-12,14-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. onal Application No
PCT/GB 94/01532

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0211363	25-02-87	DE-A- 3683210 JP-A- 62111962 US-A- 4853403	13-02-92 22-05-87 01-08-89
WO-A-9116892	14-11-91	AU-A- 7854291 US-A- 5217999	27-11-91 08-06-93

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.